FFO
APLS

Fortitude Family Office’s Apellis Pharmaceuticals APLS Stock Holding History

Fortitude Family Office’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6
Closed -$353 – 969
2024
Q1 		$353 Hold
6
– – ﹤0.01% 935
2023
Q4 		$359 Buy
+6
New +$304 ﹤0.01% 982

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fortitude Family Office's APLS Position: Q2 2024 in Review

Fortitude Family Office sold out of Apellis Pharmaceuticals (APLS) in Q2 2024, closing a stake of 6 shares — an estimated $353 sold.

Fortitude Family Office first reported a position in APLS in Q4 2023 and held it in 2 quarters. The position peaked at $359 in Q4 2023. 263 funds tracked by Wall St. Rank hold APLS as of Q2 2024.

  • Fortitude Family Office reported no remaining Apellis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Fortitude Family Office sold 6 Apellis Pharmaceuticals shares in Q2 2024, an estimated $353.
  • Fortitude Family Office first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Fortitude Family Office's Apellis Pharmaceuticals position peaked at $359 in Q4 2023.
  • 263 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2024.

Based on Fortitude Family Office's 13F filing for Q2 2024, filed 10 Jul 2024.